Combined Immunotherapies in Metastatic ER+ Breast Cancer
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic
breast cancer are eligible to a randomized trial. Patients receiving standard first line
therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to
also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.